Idera Pharmaceuticals is a clinical-stage biopharmaceutical company involved in the discovery, development, and commercialization of innovative therapeutics for oncology and rare diseases. The company has developed two distinct proprietary drug-discovery technology platforms: Toll-like receptor and third-generation antisense technology. The Toll-like receptor technology helped the company create synthetic oligonucleotide-based drug candidates. The 3GA technology is used to create drug candidates to turn off the RNA messengers associated with genes causing various diseases.